Pharma: Other News To Note
• Takeda Pharmaceutical Co. Ltd., of Osaka, Japan, and H. Lundbeck A/S, of Copenhagen, Denmark, said the FDA accepted for filing the companies' new drug application for vortioxetine for the treatment of major depressive disorder in adults. A PDUFA date of Oct. 2, 2013, is anticipated. Takeda and Lundbeck also disclosed the proposed brand name of Brintellix for vortioxetine.
Sign up for Perspectives FREE e-mail newsletter.
Outside the U.S.: 1-404-262-5423
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST